Literature DB >> 4876301

The effects of daily administration of carphenazine on attention in the schizophrenic patient.

M H Orzack, C Kornetsky, H Freeman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1967        PMID： 4876301     DOI： 10.1007/BF00401506

Source DB:  PubMed          Journal:  Psychopharmacologia


× No keyword cloud information.
  12 in total

1.  SENSORY CHANGES WITH PHENOTHIAZINE MEDICATION IN SCHIZOPHRENIC PATIENTS.

Authors:  D N LLOYD; J R NEWBROUGH
Journal:  J Nerv Ment Dis       Date:  1964-08       Impact factor: 2.254

2.  Quantitative electroencephalographic analysis of naturally occurring (schizophrenic) and drug-induced psychotic states in human males

Authors:  L GOLDSTEIN; H B MURPHREE; A A SUGERMAN; C C PFEIFFER; E H JENNEY
Journal:  Clin Pharmacol Ther       Date:  1963 Jan-Feb       Impact factor: 6.875

Review 3.  ON THE DISSIMILAR EFFECTS OF DRUGS ON THE DIGIT SYMBOL SUBSTITUTION AND CONTINOUS PERFORMANCE TESTS. A REVIEW AND PRELIMINARY INTEGRATION OF BEHAVIORAL AND PHYSIOLOGICAL EVIDENCE.

Authors:  A F MIRSKY; C KORNETSKY
Journal:  Psychopharmacologia       Date:  1964-02-12

4.  Level of arousal and the subclassification of schizophrenia.

Authors:  P H VENABLES; J K WING
Journal:  Arch Gen Psychiatry       Date:  1962-08

5.  EEG effects of carphenazine.

Authors:  M J HOSKO
Journal:  Dis Nerv Syst       Date:  1961-02

6.  Activation: a neuropsychological dimension.

Authors:  R B MALMO
Journal:  Psychol Rev       Date:  1959-11       Impact factor: 8.934

7.  The psychological significance of the concept of arousal or activation.

Authors:  E DUFFY
Journal:  Psychol Rev       Date:  1957-09       Impact factor: 8.934

8.  The effects of chlorpromazine and secobarbital under two conditions of reinforcement on the performance of chronic schizophrenic subjects.

Authors:  A Latz; C Kornetsky
Journal:  Psychopharmacologia       Date:  1965-02-15

9.  A research note on some of the critical factors on the dissimilar effects of chlorpromazine and secobarbital on the digit symbol substitution and continuous performance tests.

Authors:  C Kornetsky; M H Orzack
Journal:  Psychopharmacologia       Date:  1964-07-06

10.  Electro-cerebral activity in schizophrenics and non-psychotic subjects: quantitative EEG amplitude analysis.

Authors:  L Goldstein; A A Sugerman; H Stolberg; H B Murphree; C C Pfeiffer
Journal:  Electroencephalogr Clin Neurophysiol       Date:  1965-10
View more
  6 in total

1.  Facilitation of latent inhibition by haloperidol in rats.

Authors:  I Weiner; J Feldon
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

2.  CNS effects of propranolol in man.

Authors:  M H Orzack; R Branconnier; G Gardos
Journal:  Psychopharmacologia       Date:  1973

3.  Attention/vigilance in schizophrenia: performance results from a large multi-site study of the Consortium on the Genetics of Schizophrenia (COGS).

Authors:  Keith H Nuechterlein; Michael F Green; Monica E Calkins; Tiffany A Greenwood; Raquel E Gur; Ruben C Gur; Laura C Lazzeroni; Gregory A Light; Allen D Radant; Larry J Seidman; Larry J Siever; Jeremy M Silverman; Joyce Sprock; William S Stone; Catherine A Sugar; Neal R Swerdlow; Debby W Tsuang; Ming T Tsuang; Bruce I Turetsky; David L Braff
Journal:  Schizophr Res       Date:  2015-03-04       Impact factor: 4.939

4.  Attention and clinical symptoms in schizophrenia.

Authors:  B Cornblatt; M Obuchowski; D B Schnur; J D O'Brien
Journal:  Psychiatr Q       Date:  1997

Review 5.  The Consortium on the Genetics of Schizophrenia: neurocognitive endophenotypes.

Authors:  Raquel E Gur; Monica E Calkins; Ruben C Gur; William P Horan; Keith H Nuechterlein; Larry J Seidman; William S Stone
Journal:  Schizophr Bull       Date:  2006-11-13       Impact factor: 9.306

Review 6.  Psychopharmacological approaches to modulating attention in the five-choice serial reaction time task: implications for schizophrenia.

Authors:  Y Chudasama; T W Robbins
Journal:  Psychopharmacology (Berl)       Date:  2004-04-08       Impact factor: 4.530
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.